Search the Site

Twitter

test tubes

$POZN Strong Balance Sheet and Near-Term Phase 3 Results for POZEN

publication date: Mar 7, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Written by Mike Havrilla - POZEN (NASDAQ:POZN) is a specialty pharmaceutical company focused on the development of unique combination therapies, including two previously FDA approved products partnered with big pharma and a third product candidate in late-stage Phase 3 clinical development that is summarized below.


Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:

FREE NEWSLETTER

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database (updated daily)
- Members Only Live Interactive Webinars 
- Weekly Watchlist
- Email / SMS (Text Message) Alerts of critical news
- A More Detailed FDA Calendar
- Direct Email Communication
- Affiliate Program

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.